Name | Agnuside |
Description | Agnuside (chasteberry oil) inhibits COX-2 (IC50: 0.026 mg/ml) but exhibits less than 10% inhibition of COX-1 at this concentration. It also inhibits 46.3, 66.8, and 82.1% of P-glycoprotein (P-gp) ATPase activity at concentrations of 5, 25, and 100 μM, respectively. |
In vitro | Agnuside (0.1-10 μM) induces proliferation of MCF-7 breast cancer cells, an effect that is inhibited by the estrogen receptor antagonist fulvestrant [2]. |
In vivo | Agnuside (50 mg/kg) reduces acetic acid-induced writhing in mice indicating analgesia.3 It also suppresses production of the pro-inflammatory mediators' prostaglandin E2 (PGE2) and leukotriene B4 and the T cell-mediated cytokines IL-2, TNF-α, INF-γ, IL-4, IL-10, and IL-17 in splenocytes and arthritic paw tissue from arthritic adrenalectomized rats.4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (107.19 mM)
|
Keywords | Agnoside | Inhibitor | inhibit | Prostaglandin Receptor | Agnuside |
Inhibitors Related | Bismuth Subsalicylate | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | trans-Cinnamaldehyde | Paradol | Indomethacin sodium hydrate | Salicylic acid | Glafenine | Revaprazan hydrochloride |
Related Compound Libraries | Traditional Chinese Medicine Monomer Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Selected Plant-Sourced Compound Library | Saccharide and Glycoside Natural Product Library | Neuroprotective Compound Library | Anti-Aging Compound Library | GPCR Compound Library | Ion Channel Targeted Library |